{"meshTags":["Pyridones","Antineoplastic Agents","Imidazoles","United States","Proto-Oncogene Proteins B-raf","Oximes","Treatment Outcome","United States Food and Drug Administration","Antineoplastic Combined Chemotherapy Protocols","Pyrimidinones","Melanoma","Molecular Targeted Therapy","Humans"],"meshMinor":["Pyridones","Antineoplastic Agents","Imidazoles","United States","Proto-Oncogene Proteins B-raf","Oximes","Treatment Outcome","United States Food and Drug Administration","Antineoplastic Combined Chemotherapy Protocols","Pyrimidinones","Melanoma","Molecular Targeted Therapy","Humans"],"genes":["BRAF V600K"],"publicationTypes":["News"],"abstract":"The U.S. Food and Drug Administration approved the use of trametinib and dabrafenib in combination for patients with metastatic or unresectable melanoma with BRAF V600K or V600E mutations-the first combination therapy approved for the disease. ","title":"Combination therapy approved for melanoma.","pubmedId":"24596183"}